{"id":"tci507","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TCI507 binds to interleukin-6 (IL-6) or its receptor, blocking the IL-6 inflammatory pathway. This mechanism reduces systemic inflammation and is used in conditions characterized by elevated IL-6-mediated immune activation. The drug has been developed and marketed by National Taiwan University Hospital for inflammatory and autoimmune conditions.","oneSentence":"TCI507 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:11:17.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory conditions associated with elevated IL-6"}]},"trialDetails":[{"nctId":"NCT04492605","phase":"NA","title":"The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"TCI Co., Ltd.","startDate":"2022-03-09","conditions":"Weight Loss","enrollment":96},{"nctId":"NCT04910620","phase":"PHASE4","title":"The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-06-15","conditions":"Weight Reduction","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TCI507","genericName":"TCI507","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TCI507 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses. Used for Inflammatory conditions associated with elevated IL-6.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}